Medical Professional Publications

Pharmacy and Therapeutics Committee Updates

(From the October 2014 Issue of MedStat)

For more detailed information, contact Kimberly Novak at Kimberly.Novak@NationwideChildren.org.

The following actions were taken at the September 4 Pharmacy & Therapeutics Committee meeting.

The clinic medication stock list for IDC/FACES was APPROVED.

Allergy/Immunology Clinic sample requests were APPROVED for Oralair sublingual tablet started pack and Ragwitek 12 Amb a 1-U sublingual started pack.

Chlorpromazine (Thorazine®) was APPROVED for formulary addition.  Initiation of therapy in pediatric patients for psychiatric indications should be limited to prescribing by or in consultation with Behavioral Health or Psychiatry which will be guided by Epic alerts.  The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

Perphenazine (Trilafon®) was APPROVED for formulary addition.  Initiation of therapy in pediatric patients for psychiatric indications should be limited to prescribing by or in consultation with Behavioral Health or Psychiatry which will be guided by Epic alerts.  The monograph will be posted on the P&T intranet website. A review of formulary drug use will be presented in six months.

The new non-formulary IV drug card: Eculizumab (Soliris®) IV drug card was APPROVED.  It is viewable in the online drug card database.

Nationwide Children's Hospital
700 Children's Drive Columbus, Ohio 43205 614.722.2000